Disclosed is the use of a unit dose of glycopyrrolate for the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease (COPD), wherein the unit dose comprises a therapeutically effective amount of up to 250µg of glycopyrrolate as the sole therapeutic agent and wherein the medicament is adapted for administration by a nebulizer. Further disclosed is the use of a unit dose of glycopyrrolate for the manufacture of a medicament for the relief of one or more symptoms of chronic obstructive pulmonary disease (COPD) for at least 24 hours, wherein the unit dose comprises a therapeutically effective amount of up to 250µg of glycopyrrolate as the sole therapeutic agent, and wherein the medicament is an aqueous inhalation solution adapted for administration by a high efficiency nebulizer.
